Zinc ion framework improves immunotherapy drug delivery

Written by The Nanomed Zone, Celeste Brady (Future Science Group)

Research from a collaborative project led by scientists from the King Abdullah University of Science and Technology (KAUST; Thuwal, Saudi Arabia), published in Science Advances, has revealed a potential novel drug delivery system for the treatment of leukemia and solid tumors. Cancer immunotherapy modulates the immune system to encourage it to attack cancer cells. Immune checkpoint inhibitors, such as nivolumab, disrupt cancer cells’ immune evasion strategies that deactivate T cells. Removing the cancer’s defense against the immune system and activating T cells is an effective method of killing cancer cells. However, these therapies can have intense and debilitating adverse effects...

To view this content, please register now for access

Join our member community for FREE to access a collection of journal and online-only features, including:

  • Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
  • The latest news and journal updates delivered straight to your inbox when you want it
  • Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
  • Priority registration to webinars, panel discussions and events
  • Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!